- Polycystic ovary syndrome
This article needs more medical references for verification.
Please review the contents of the article and add the appropriate references if you can.
Help may also be requested at Wikipedia:WikiProject Medicine.
Please remove this message after the article has been corrected.
Polycystic Ovary Syndrome. Classification and external resources
A polycystic ovary (aka PCO) shown on an ultrasound image. PCO no longer defines PCOS but is a common symptom. As many as 30% or more of women with PCOS do not have PCO as a sign.
ICD-10 E28.2 ICD-9 256.4 OMIM 184700 eMedicine med/2173 ped/2155 radio/565 MeSH D011085
Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorders. PCOS is a complex, heterogeneous disorder of uncertain aetiology, but there is strong evidence that it can to a large degree be classified as a genetic disease.
PCOS produces symptoms in approximately 5% to 10% of women of reproductive age (12–45 years old). It is thought to be one of the leading causes of female subfertility  and the most frequent endocrine problem in women of reproductive age.
The principal features are anovulation, resulting in irregular menstruation, amenorrhea, ovulation-related infertility, and polycystic ovaries; excessive amounts or effects of androgenic (masculinizing) hormones, resulting in acne and hirsutism; and insulin resistance, often associated with obesity, Type 2 diabetes, and high cholesterol levels. The symptoms and severity of the syndrome vary greatly among affected women.
- 1 Names
- 2 Definition
- 3 Signs and symptoms
- 4 Diagnosis
- 5 Cause
- 6 Pathogenesis
- 7 Management
- 8 Prognosis
- 9 History
- 10 See also
- 11 References
- 12 External links
Other names for this syndrome include polycystic ovary disease, functional ovarian hyperandrogenism, ovarian hyperthecosis, sclerocystic ovary syndrome, and Stein-Leventhal syndrome. (The last is the original name, now used - if at all - only for the subset of patients with all of amenorrhea with infertility, hirsutism, and enlarged polycystic ovaries.)
Most common names for this disease derive from a typical finding on medical images, called a polycystic ovary. A polycystic ovary has an abnormally large number of developing eggs visible near its surface, looking like many small cysts or a string of pearls.
Two definitions are commonly used:
- In 1990 a consensus workshop sponsored by the NIH/NICHD suggested that a patient has PCOS if she has all of the following:
- signs of androgen excess (clinical or biochemical)
- other entities are excluded that would cause polycystic ovaries
- In 2003 a consensus workshop sponsored by ESHRE/ASRM in Rotterdam indicated PCOS to be present if any 2 out of 3 criteria are met
- oligoovulation and/or anovulation
- excess androgen activity
- polycystic ovaries (by gynecologic ultrasound)
The Rotterdam definition is wider, including many more patients, most notably patients without androgen excess. Critics say that findings obtained from the study of patients with androgen excess cannot necessarily be extrapolated to patients without androgen excess.
- Androgen Excess PCOS Society
- In 2006 the Androgen Excess PCOS Society suggested a tightening of the diagnostic criteria to all of:
- excess androgen activity
- oligoovulation/anovulation and/or polycystic ovaries
- other entities are excluded that would cause excess androgen activity
The prevalence of PCOS depends on the choice of diagnostic criteria. One community-based prevalence study using the Rotterdam criteria found that about 18% of women had PCOS, and that 70% of them were previously undiagnosed.
Signs and symptoms
Common symptoms of PCOS include
- Menstrual disorders: mostly oligomenorrhea (few menstrual periods) or amenorrhea (no menstrual periods), but other types of menstrual disorders may also occur.
- Infertility: generally resulting from chronic anovulation (lack of ovulation).
- High levels of masculinizing hormones: mostly acne and hirsutism (male pattern of hair growth), but may produce hypermenorrhea (very frequent menstrual periods) or other symptoms. Approximately three-quarters of patients with PCOS (by the diagnostic criteria of NIH/NICHD 1990) have evidence of hyperandrogenemia.
- Metabolic syndrome: This appears as a tendency towards central obesity and other symptoms associated with insulin resistance. Serum insulin, insulin resistance and homocysteine levels are significantly higher in subjects having PCOS.
Not all women with PCOS have polycystic ovaries (PCO), nor do all women with ovarian cysts have PCOS; although a pelvic ultrasound is a major diagnostic tool, it is not the only one. The diagnosis is straightforward using the Rotterdam criteria, even when the syndrome is associated with a wide range of symptoms.
Standard diagnostic assessments
- History-taking, specifically for menstrual pattern, obesity, hirsutism, and the absence of breast development. A clinical prediction rule found that these four questions can diagnose PCOS with a sensitivity of 77.1% (95% confidence interval [CI] 62.7%–88.0%) and a specificity of 93.8% (95% CI 82.8%–98.7%).
- Gynecologic ultrasonography, specifically looking for small ovarian follicles. These are believed to be the result of disturbed ovarian function with failed ovulation, reflected by the infrequent or absent menstruation that is typical of the condition. In a normal menstrual cycle, one egg is released from a dominant follicle - essentially a cyst that bursts to release the egg. After ovulation the follicle remnant is transformed into a progesterone-producing corpus luteum, which shrinks and disappears after approximately 12–14 days. In PCOS, there is a so called "follicular arrest", i.e., several follicles develop to a size of 5–7 mm, but not further. No single follicle reaches the preovulatory size (16 mm or more). According to the Rotterdam criteria, 12 or more small follicles should be seen in an ovary on ultrasound examination. The follicles may be oriented in the periphery, giving the appearance of a 'string of pearls'. The numerous follicles contribute to the increased size of the ovaries, that is, 1.5 to 3 times larger than normal.
- Laparoscopic examination may reveal a thickened, smooth, pearl-white outer surface of the ovary. (This would usually be an incidental finding if laparoscopy were performed for some other reason, as it would not be routine to examine the ovaries in this way to confirm a diagnosis of PCOS.)
- Serum (blood) levels of androgens (male hormones), including androstenedione and testosterone may be elevated. Dehydroepiandrosterone sulfate levels above 700-800mcg/dL are highly suggestive of adrenal dysfunction because DHEA-S is made exclusively by the adrenal glands. The free testosterone level is thought to be the best measure, with ~60% of PCOS patients demonstrating supranormal levels. The Free androgen index of the ratio of testosterone to sex hormone-binding globulin (SHBG) is high and is meant to be a predictor of free testosterone, but is a poor parameter for this and is no better than testosterone alone as a marker for PCOS, possibly because FAI is correlated with the degree of obesity.
- Some other blood tests are suggestive but not diagnostic. The ratio of LH (Luteinizing hormone) to FSH (Follicle stimulating hormone) is greater than 1:1 (sometimes more than 3:1), as tested on Day 3 of the menstrual cycle. The pattern is not very specific and was present in less than 50% in one study. There are often low levels of sex hormone binding globulin, particularly among obese or overweight women.
Common assessments for associated conditions or risks
- Fasting biochemical screen and lipid profile
- 2-hour oral glucose tolerance test (GTT) in patients with risk factors (obesity, family history, history of gestational diabetes) may indicate impaired glucose tolerance (insulin resistance) in 15-33% of women with PCOS. Frank diabetes can be seen in 65–68% of women with this condition. Insulin resistance can be observed in both normal weight and overweight patients, although it is more common in the latter (and in those matching the stricter NIH criteria for diagnosis); 50-80% of PCOS patients may have insulin resistance at some level.
- Fasting insulin level or GTT with insulin levels (also called IGTT). Elevated insulin levels have been helpful to predict response to medication and may indicate women who will need higher dosages of metformin or the use of a second medication to significantly lower insulin levels. Elevated blood sugar and insulin values do not predict who responds to an insulin-lowering medication, low-glycemic diet, and exercise. Many women with normal levels may benefit from combination therapy. A hypoglycemic response in which the two-hour insulin level is higher and the blood sugar lower than fasting is consistent with insulin resistance. A mathematical derivation known as the HOMAI, calculated from the fasting values in glucose and insulin concentrations, allows a direct and moderately accurate measure of insulin sensitivity (glucose-level x insulin-level/22.5).
- Glucose tolerance testing (GTT) instead of fasting glucose can increase diagnosis of increased glucose tolerance and frank diabetes among patients with PCOS according to a prospective controlled trial. While fasting glucose levels may remain within normal limits, oral glucose tests revealed that up to 38% of asymptomatic women with PCOS (versus 8.5% in the general population) actually had impaired glucose tolerance, 7.5% of those with frank diabetes according to ADA guidelines.
Other causes of irregular or absent menstruation and hirsutism, such as hypothyroidism, congenital adrenal hyperplasia (21-hydroxylase deficiency), Cushing's syndrome, hyperprolactinemia, androgen secreting neoplasms, and other pituitary or adrenal disorders, should be investigated. PCOS has been reported in other insulin-resistant situations such as acromegaly.
PCOS is a complex, heterogeneous disorder of uncertain aetiology. There is strong evidence that it can to a large degree be classified as a genetic disease. Such evidence include familial clustering of cases, greater concordance in monozygotic compared with dizygotic twins and heritability of endocrine and metabolic features of PCOS.
The genetic component appears to be inherited in an autosomal dominant fashion with high genetic penetrance but variable expressivity in females, meaning that each child has a 50% chance of inheriting the predisposing genetic pattern from a parent, and if a daughter receives the pattern, then the daughter will have the disease to some extent. The genetic pattern can be inherited from either the father or the mother, and can be passed along to both sons, who may be asymptomatic carriers or may have symptoms such as early baldness and/or excessive hair, and daughters, who will show signs of PCOS. The allele appears to manifest itself at least partially via heightened androgen levels secreted by ovarian follicle theca cells from women with the allele. Any exact gene that is affected has not yet been identified. The severity of PCOS appears to be largely determined by factors such as obesity.
Polycystic ovaries develop when the ovaries are stimulated to produce excessive amounts of male hormones (androgens), particularly testosterone, by either one or a combination of the following (almost certainly combined with genetic susceptibility):
- the release of excessive luteinizing hormone (LH) by the anterior pituitary gland
- through high levels of insulin in the blood (hyperinsulinaemia) in women whose ovaries are sensitive to this stimulus
Alternatively or as well, reduced levels of sex-hormone binding globulin can result in increased free androgens.
The syndrome acquired its most widely used name due to the common sign on ultrasound examination of multiple (poly) ovarian cysts. These "cysts" are actually immature follicles, not cysts ("polyfollicular ovary syndrome" would have been a more accurate name). The follicles have developed from primordial follicles, but the development has stopped ("arrested") at an early antral stage due to the disturbed ovarian function. The follicles may be oriented along the ovarian periphery, appearing as a 'string of pearls' on ultrasound examination.
A majority of patients with PCOS have insulin resistance and/or are obese. Their elevated insulin levels contribute to or cause the abnormalities seen in the hypothalamic-pituitary-ovarian axis that lead to PCOS. Hyperinsulinemia increases GnRH pulse frequency, LH over FSH dominance, increased ovarian androgen production, decreased follicular maturation, and decreased SHBG binding; all these steps contribute to the development of PCOS. Insulin resistance is a common finding among patients of normal weight as well as overweight patients.
In many cases PCOS is characterised by a complex positive feedback loop of insulin resistance and hyperandrogenism. In most cases it can not be determined which (if any) of those two should be regarded causative. Experimental treatment with either antiandrogens or insulin sensitizing agents improves both hyperandrogenism and insulin resistance.
Adipose tissue possesses aromatase, an enzyme that converts androstenedione to estrone and testosterone to estradiol. The excess of adipose tissue in obese patients creates the paradox of having both excess androgens (which are responsible for hirsutism and virilization) and estrogens (which inhibits FSH via negative feedback).
One study in the United Kingdom concluded that the risk of PCOS development was higher in lesbian women than in heterosexuals. However, two subsequent studies of women with PCOS have not replicated this finding.
It has previously been suggested that the excessive androgen production in PCOS could be caused by a decreased serum level of IGFBP-1, in turn increasing the level of free IGF-I which stimulates ovarian androgen production, but recent data concludes this mechanism to be unlikely.
PCOS has also been associated with a specific FMR1 sub-genotype. The research suggests that women who have heterozygous-normal/low FMR1 have polycystic-like symptoms of excessive follicle-activity and hyperactive ovarian function.
Medical treatment of PCOS is tailored to the patient's goals. Broadly, these may be considered under four categories:
- Lowering of insulin levels
- Restoration of fertility
- Treatment of hirsutism or acne
- Restoration of regular menstruation, and prevention of endometrial hyperplasia and endometrial cancer
In each of these areas, there is considerable debate as to the optimal treatment. One of the major reasons for this is the lack of large scale clinical trials comparing different treatments. Smaller trials tend to be less reliable and hence may produce conflicting results.
General interventions that help to reduce weight or insulin resistance can be beneficial for all these aims, because they address what is believed to be the underlying cause.
Where PCOS is associated with overweight or obesity, successful weight loss is the most effective method of restoring normal ovulation/menstruation, but many women find it very difficult to achieve and sustain significant weight loss. Low-carbohydrate diets and sustained regular exercise may help. Some experts recommend a low GI diet in which a significant part of total carbohydrates are obtained from fruit, vegetables and whole grain sources. Vitamin D deficiency may play some role in the development of the metabolic syndrome, so treatment of any such deficiency is indicated.
Reducing insulin resistance by improving insulin sensitivity through medications such as metformin, and the newer thiazolidinedione (glitazones), have been an obvious approach and initial studies seemed to show effectiveness. Although metformin is not licensed for use in PCOS, the United Kingdom's National Institute for Health and Clinical Excellence recommended in 2004 that women with PCOS and a body mass index above 25 be given metformin when other therapy has failed to produce results. However subsequent reviews in 2008 and 2009 have noted that randomised control trials have in general not shown the promise suggested by the early observational studies.
Not all women with PCOS have difficulty becoming pregnant. For those who do, anovulation or infrequent ovulation is a common cause. Other factors include changed levels of gonadotropins, hyperandrogenemia and hyperinsulinemia. Like women without PCOS, women with PCOS who are ovulating may be infertile due to other causes, such as tubal blockages due to a history of sexually transmitted diseases.
For overweight, anovulatory women with PCOS, weight loss and diet adjustments, especially to reduce the intake of simple carbohydrates, are associated with resumption of natural ovulation.
For those who after weight loss still are anovulatory or for anovulatory lean women, then the ovulation-inducing medications clomiphene citrate and FSH are the principal treatments used to promote ovulation. Previously, the anti-diabetes medication metformin was recommended treatment for anovulation, but it appears less effective than clomiphene.
For patients who do not respond to clomiphene, diet and lifestyle modification, there are options available including assisted reproductive technology procedures such as controlled ovarian hyperstimulation with follicle-stimulating hormone (FSH) injections followed by in vitro fertilisation (IVF).
Though surgery is not commonly performed, the polycystic ovaries can be treated with a laparoscopic procedure called "ovarian drilling" (puncture of 4-10 small follicles with electrocautery, laser, or biopsy needles), which often results in either resumption of spontaneous ovulations or ovulations after adjuvant treatment with clomiphene or FSH. (Ovarian wedge resection is no longer used as much due to complications such as adhesions and the presence of frequently-effective medications.) There are, however, concerns about the long-term effects of ovarian drilling on ovarian function.
Hirsutism and acne
When appropriate (e.g. in women of child-bearing age who require contraception), a standard contraceptive pill is frequently effective in reducing hirsutism. A common choice of contraceptive pill is one that contains cyproterone acetate; in the UK the available brands are Dianette/Diane. Cyproterone acetate is a progestogen with anti-androgen effects that block the action of male hormones that are believed to contribute to acne and the growth of unwanted facial and body hair. On the other hand, progestogens such as norgestrel and levonorgestrel should be avoided due to their androgenic effects.
Other drugs with anti-androgen effects include flutamide and spironolactone, which can give some improvement in hirsutism. Spironolactone is probably the most-commonly used drug in the US. Metformin can reduce hirsutism, perhaps by reducing insulin resistance, and is often used if there are other features such as insulin resistance, diabetes or obesity that should also benefit from metformin. Eflornithine (Vaniqa) is a drug which is applied to the skin in cream form, and acts directly on the hair follicles to inhibit hair growth. It is usually applied to the face. Medications that reduce acne by indirect hormonal effects also include ergot dopamine agonists such as bromocriptine. 5-alpha reductase inhibitors (such as finasteride and dutasteride) may also be used; they work by blocking the conversion of testosterone to dihydrotestosterone (the latter of which is responsible for most hair growth alterations and androgenic acne).
Although these agents have shown significant efficacy in clinical trials (for oral contraceptives, in 60-100% of individuals), the reduction in hair growth may not be enough to eliminate the social embarrassment of hirsutism, or the inconvenience of plucking/shaving. Individuals vary in their response to different therapies. It is usually worth trying other drug treatments if one does not work, but drug treatments do not work well for all individuals. For removal of facial hairs, electrolysis or laser treatments are - at least for some - faster and more efficient alternatives than the above mentioned medical therapies.
Menstrual irregularity and endometrial hyperplasia
If fertility is not the primary aim, then menstruation can usually be regulated with a contraceptive pill, though the effects are caused by substituted hormones that can easily cause more problems if the pill is taken for a long period of time. The purpose of regulating menstruation is essentially for the woman's convenience, and perhaps her sense of well-being; there is no medical requirement for regular periods, so long as they occur sufficiently often (see below).
If a regular menstrual cycle is not desired, then therapy for an irregular cycle is not necessarily required - most experts consider that if a menstrual bleed occurs at least every three months, then the endometrium (womb lining) is being shed sufficiently often to prevent an increased risk of endometrial abnormalities or cancer. If menstruation occurs less often or not at all, some form of progestogen replacement is recommended. Some women prefer a uterine progestogen device such as the intrauterine system (Mirena) or the progestin implant (Implanon), which provides simultaneous contraception and endometrial protection for years. An alternative is oral progestogen taken at intervals (e.g. every three months) to induce a predictable menstrual bleeding.
At least two inositol isomers - D-chiro-inositol and myo-inositol have shown considerable promise in improving PCOS. They are generally very well tolerated and have been evaluated by several small-scale trials. Inositol has no documented side-effects and is a naturally occurring human metabolite known to be involved in insulin metabolism. DCI is regulated as a dietary supplement in the United States. Myo-inositol is naturally present in many foods although not readily digestible from most of them.
Women with PCOS are at risk for the following:
- Endometrial hyperplasia and endometrial cancer (cancer of the uterine lining) are possible, due to overaccumulation of uterine lining, and also lack of progesterone resulting in prolonged stimulation of uterine cells by estrogen. It is not clear if this risk is directly due to the syndrome or from the associated obesity, hyperinsulinemia, and hyperandrogenism.
- Insulin resistance/Type II diabetes. A review published in 2010 concluded that women with PCOS had an elevated prevalence of insulin resistance and type II diabetes, even when controlling for body mass index (BMI). PCOS also makes a woman, particularly if obese, prone to gestational diabetes.
- High blood pressure, particularly if obese and/or during pregnancy
- Depression/Depression with Anxiety 
- Dyslipidemia - disorders of lipid metabolism — cholesterol and triglycerides. PCOS patients show decreased removal of atherosclerosis-inducing remnants, seemingly independent of insulin resistance/Type II diabetes.
- Cardiovascular disease, with a meta-analysis estimating a 2-fold risk of arterial disease for women with PCOS relative to women without PCOS, independent of BMI.
- Weight gain
- Sleep apnea, particularly if obesity is present
- Non-alcoholic fatty liver disease, again particularly if obesity is present
- Acanthosis nigricans (patches of darkened skin under the arms, in the groin area, on the back of the neck)
- Autoimmune thyroiditis 
Early diagnosis and treatment may reduce the risk of some of these, such as type 2 diabetes and heart disease.
- Androgen-dependent syndromes
- PCOS Challenge (reality television series)
- ^ a b c Page 836 (Section: Polycystic ovary syndrome) in: Fauser, B. C. J. M.; Diedrich, K.; Bouchard, P.; Dominguez, F.; Matzuk, M.; Franks, S.; Hamamah, S.; Simon, C. et al. (2011). "Contemporary genetic technologies and female reproduction". Human Reproduction Update 17 (6): 829–847. doi:10.1093/humupd/dmr033. PMC 3191938. PMID 21896560. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3191938.
- ^ a b c d e Legro RS; Strauss JF (September 2002). "Molecular progress in infertility: polycystic ovary syndrome". Fertility and Sterility 78 (3): 569–576. PMID 12215335.
- ^ a b c d Diamanti-Kandarakis E; Kandarakis H, Legro RS (August 2006). "The role of genes and environment in the etiology of PCOS". Endocrine 30 (1): 19–26. PMID 17185788.
- ^ a b Goldenberg N, Glueck C (2008). "Medical therapy in women with polycystic ovary syndrome before and during pregnancy and lactation". Minerva Ginecol 60 (1): 63–75. PMID 18277353.
- ^ a b Boomsma CM, Fauser BC, Macklon NS (2008). "Pregnancy complications in women with polycystic ovary syndrome". Semin. Reprod. Med. 26 (1): 72–84. doi:10.1055/s-2007-992927. PMID 18181085.
- ^ Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (June 2004). "The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population". Journal of Clinical Endocrinology & Metabolism 89 (6): 2745–9. doi:10.1210/jc.2003-032046. PMID 15181052.
- ^ a b c d e f g h i j k l m n o p H Teede; A Deeks; L Moran (30 June 2010). "Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan". BMC Medicine (BioMedCentral) 8: 41. doi:10.1186/1741-7015-8-41. http://www.biomedcentral.com/1741-7015/8/41. Retrieved 14 November 2011.
- ^ a b c d Greg Marrinan (20 April 2011). "Imaging in Polycystic Ovary Disease". In Eugene C. Lin. eMedicine. eMedicine. http://emedicine.medscape.com/article/404754-overview. Retrieved 19 November 2011
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z Mayo Clinic Staff (4 April 2011). "Polycystic Ovary Syndrome - All". MayoClinic.com. Mayo Clinic. http://www.mayoclinic.com/health/polycystic-ovary-syndrome/DS00423/METHOD=print&DSECTION=all. Retrieved 15 November 2011.
- ^ "What is Polycystic Ovary Syndrome (PCOS)?". Verity - PCOS Charity. Verity. 2011. http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos. Retrieved 21 November 2011.
- ^ a b c d e f g h Richard Scott Lucidi (25 October 2011). "Polycystic Ovarian Syndrome". eMedicine. http://emedicine.medscape.com/article/256806-overview#showall. Retrieved 19 November 2011.
- ^ Azziz R (March 2006). "Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature". Journal of Clinical Endocrinology & Metabolism 91 (3): 781–785. doi:10.1210/jc.2005-2153. PMID 16418211.
- ^ a b The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group (2004). "Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS)". Human Reproduction 19 (1): 41–47. doi:10.1093/humrep/deh098. PMID 14688154. http://humrep.oxfordjournals.org/content/19/1/41.long. Retrieved 14 November 2011.
- ^ Carmina E (February 2004). "Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.". Minerva ginecologica 56 (1): 1–6. PMID 14973405.
- ^ Hart R, Hickey M, Franks S (October 2004). "Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome". Best Practice & Research Clinical Obstetrics & Gynaecology 18 (5): 671–83. doi:10.1016/j.bpobgyn.2004.05.001. PMID 15380140.
- ^ Christine Cortet-Rudelli, Didier Dewailly (Sep 21 2006). "Diagnosis of Hyperandrogenism in Female Adolescents". Hyperandrogenism in Adolescent Girls. Armenian Health Network, Health.am. http://www.health.am/gyneco/more/diagnosis-of-hyperandrogenism-in-female/. Retrieved 2006-11-21.
- ^ a b Huang A, Brennan K, Azziz R (April 2010). "Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria". Fertil. Steril. 93 (6): 1938–41. doi:10.1016/j.fertnstert.2008.12.138. PMC 2859983. PMID 19249030. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2859983.
- ^ a b Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M (April 2010). "The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome". Fertil. Steril. 93 (6): 1864–9. doi:10.1016/j.fertnstert.2008.12.024. PMID 19171332.
- ^ Pedersen SD, Brar S, Faris P, Corenblum B (2007). "Polycystic ovary syndrome: validated questionnaire for use in diagnosis". Canadian Family Physician 53 (6): 1042–7, 1041. PMC 1949220. PMID 17872783. http://www.cfp.ca/cgi/content/full/53/6/1041#T50531041. - see Table 5 Clinical tool for diagnosis of polycystic ovary syndrome
- ^ Somani N, Harrison S, Bergfeld WF (2008). "The clinical evaluation of hirsutism". Dermatologic therapy 21 (5): 376–91. doi:10.1111/j.1529-8019.2008.00219.x. PMID 18844715.
- ^ a b c d e f g h "Polycystic Ovarian Syndrome Workup". eMedicine. 25 October 2011. http://emedicine.medscape.com/article/256806-workup#showall. Retrieved 19 November 2011.
- ^ Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA (July 2007). "Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome". Saudi Med J 28 (7): 1039–43. PMID 17603706.
- ^ Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN (March 1992). "Which hormone tests for the diagnosis of polycystic ovary syndrome?". Br J Obstet Gynaecol 99 (3): 232–8. doi:10.1111/j.1471-0528.1992.tb14505.x. PMID 1296589.
- ^ Li X, Lin JF (December 2005). "[Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]" (in Chinese). Zhonghua Yi Xue Za Zhi 85 (46): 3266–71. PMID 16409817.
- ^ Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L (2003). "Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia". Rocz. Akad. Med. Bialymst. 48: 131–4. PMID 14737959.
- ^ a b Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999). "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women". J. Clin. Endocrinol. Metab. 84 (1): 165–9. doi:10.1210/jc.84.1.165. PMID 9920077. http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=9920077.
- ^ a b Crosignani PG, Nicolosi AE (2001). "Polycystic ovarian disease: heritability and heterogeneity". Hum. Reprod. Update 7 (1): 3–7. PMID 11212071.
- ^ a b c Strauss JF 3rd (November 2003). "Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome". Annals of the New York Academy of Sciences 997: 42–48. PMID 14644808.
- ^ a b Ada Hamosh (12 September 2011). "POLYCYSTIC OVARY SYNDROME 1; PCOS1". OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. http://omim.org/entry/184700. Retrieved 15 November 2011.
- ^ Amato P, Simpson JL (October 2004). "The genetics of polycystic ovary syndrome". Best Pract Res Clin Obstet Gynaecol 18 (5): 707–18. doi:10.1016/j.bpobgyn.2004.05.002. PMID 15380142.
- ^ Kumar Cotran Robbins: Basic Pathology 6th ed. / Saunders 1996
- ^ Thozhukat Sathyapalan; Stephen L. Atkin (2010). "Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity". Mediators of Inflammation (Hindawi) 2010: 758656. doi:10.1155/2010/758656. PMC 2852606. PMID 20396393. http://www.hindawi.com/journals/mi/2010/758656/.
- ^ Fukuoka M, Yasuda K, Fujiwara H, Kanzaki H, Mori T (1992). "Interactions between interferon gamma, tumour necrosis factor alpha, and interleukin-1 in modulating progesterone and oestradiol production by human luteinized granulosa cells in culture.". Hum Reprod 7 (10): 1361–4. PMID 1291559.
- ^ González F, Rote N, Minium J, Kirwan J (2006). "Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.". J Clin Endocrinol Metab 91 (1): 336–40. doi:10.1210/jc.2005-1696. PMID 16249279.
- ^ Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH, Prelevic G. (2004). "Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women.". JFertil Steril 82 (5): 1352–7.. doi:10.1016/j.fertnstert.2004.04.041. PMID 15533359.
- ^ Kelly, C. J.; Stenton, S. R.; Lashen, H. (2010). "Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis". Human Reproduction Update 17 (1): 4. doi:10.1093/humupd/dmq027. PMID 20634211.
- ^ “Polycystic Ovaries or Polycystic Ovary Syndrome”
- ^ Gleicher N, Weghofer A, Lee IH, Barad DH (2010). "FMR1 Genotype with Autoimmunity-Associated Polycystic Ovary-Like Phenotype and Decreased Pregnancy Chance". PLoS ONE 5 (12): e15303. doi:10.1371/journal.pone.0015303.
- ^ a b c d e f g h i j k l "Polycystic Ovarian Syndrome Treatment & Management". eMedicine. 25 October 2011. http://emedicine.medscape.com/article/256806-treatment#showall. Retrieved 19 November 2011.
- ^ Marsh K, Brand-Miller J (August 2005). "The optimal diet for women with polycystic ovary syndrome?". Br. J. Nutr. 94 (2): 154–65. doi:10.1079/BJN20051475. PMID 16115348. http://journals.cambridge.org/abstract_S0007114505001674.
- ^ Lord JM, Flight IHK, Norman RJ (2003). "Metformin in polycystic ovary syndrome: systematic review and meta-analysis". BMJ 327 (7421): 951–3. doi:10.1136/bmj.327.7421.951. PMC 259161. PMID 14576245. http://www.bmj.com/cgi/content/full/327/7421/951.
- ^ National Institute for Health and Clinical Excellence. 11 Clinical guideline 11 : Fertility: assessment and treatment for people with fertility problems . London, 2004.
- ^ Balen A (December 2008). "Metformin therapy for the management of infertility in women with polycystic ovary syndrome" (PDF). Scientific Advisory Committee Opinion Paper 13. Royal College of Obstetricians and Gynaecologists. http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf. Retrieved 2009-12-13.
- ^ Leeman L, Acharya U (August 2009). "The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence". J Obstet Gynaecol 29 (6): 467–72. doi:10.1080/01443610902829414. PMID 19697191.
- ^ Qiao, J.; Feng, H. L. (2010). "Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence". Human Reproduction Update 17 (1): 17. doi:10.1093/humupd/dmq032. PMC 3001338. PMID 20639519. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3001338.
- ^ Legro RS, Barnhart HX, Schlaff WD (2007). "Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome". N Engl J Med 356 (6): 551–66. doi:10.1056/NEJMoa063971. PMID 17287476.
- ^ "Polycystic ovary syndrome - Treatment". United Kingdom: National Health Service. 17 October 2011. http://www.nhs.uk/Conditions/Polycystic-ovarian-syndrome/Pages/Treatment.aspx. Retrieved 19 November 2011.
- ^ a b Richard Scott Lucidi (25 October 2011). "Polycystic Ovarian Syndrome Medication". eMedicine. http://emedicine.medscape.com/article/256806-medication#showall. Retrieved 19 November 2011.
- ^ "What are the health risks of PCOS?". Verity - PCOS Charity. Verity. 2011. http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos/health_risks. Retrieved 21 November 2011.
- ^ Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G (1999). "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome". N Engl J Med 340 (17): 1314–20. doi:10.1056/NEJM199904293401703. PMID 10219066.
- ^ Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E (2002). "Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome". Endocr Pract 8 (6): 417–23. PMID 15251831.
- ^ Gerli, S; Papaleo, E; Ferrari, A; Di Renzo, GC (2007). "Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS". European review for medical and pharmacological sciences 11 (5): 347–54. PMID 18074942.
- ^ Larner J (2002). "D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance". Int J Exp Diabetes Res 3 (1): 47–60. doi:10.1080/15604280212528. PMC 2478565. PMID 11900279. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2478565.
- ^ New MI (May 1993). "Nonclassical congenital adrenal hyperplasia and the polycystic ovarian syndrome.". Annals of the New York Academy of Sciences 687 (1 Intraovarian): 193–205. doi:10.1111/j.1749-6632.1993.tb43866.x. PMID 8323173.
- ^ Hardiman P, Pillay OC, Atiomo W (May 2003). "Polycystic ovary syndrome and endometrial carcinoma.". Lancet 361 (9371): 1810–2. doi:10.1016/S0140-6736(03)13409-5. PMID 12781553.
- ^ Mather KJ, Kwan F, Corenblum B (January 2000). "Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity.". Fertility and sterility 73 (1): 150–6. doi:10.1016/S0015-0282(99)00468-9. PMID 10632431.
- ^ Unfer V, Zacchè M, Serafini A, Redaelli A, Papaleo E (October 2008). "Treatment of hyperandrogenism and hyperinsulinemia in PCOS patients with essential amino acids. A pilot clinical study.". Minerva ginecologica 60 (5): 363–8. PMID 18854802.
- ^ Moran LJ, Misso ML, Wild RA, Norman RJ (May 2010). "Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis". Hum Reprod Update 16 (4): 347–63. doi:10.1093/humupd/dmq001. PMID 20159883.
- ^ Barry JA, Kuczmierzyck, AR, Hardiman, PJ (July 2011). "Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis". Hum. Reprod. 93 (6): 1948–56. PMID 21725075.
- ^ Rocha MP, Maranhão RC, Seydell TM, et al. (April 2010). "Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome". Fertil. Steril. 93 (6): 1948–56. doi:10.1016/j.fertnstert.2008.12.044. PMID 19765700.
- ^ De Groot, P. C. M.; Dekkers, O. M.; Romijn, J. A.; Dieben, S. W. M.; Helmerhorst, F. M. (2011). "PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis". Human Reproduction Update 17 (4): 495–500. doi:10.1093/humupd/dmr001. PMID 21335359.
- ^ Troischt MJ, Mehlman TR, and Nield LS (November 1, 2008). "Polycystic Ovary Syndrome: An Intriguing Diagnosis". Consultant for Pediatricians. http://www.consultantlive.com/consultant-for-pediatricians/article/1145470/1404582.
Endocrine pathology: endocrine diseases (E00–E35, 240–259) Pancreas/
pituitary axesHypothalamusPituitaryThyroidEndemic goitre · Toxic nodular goitre · Toxic multinodular goiter
Wikimedia Foundation. 2010.